These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30446583)

  • 1.
    Palacio S; Pontes L; Prado E; Arshad J; Ali R; Piha T; Bacchi CE; Mudad R; Lopes G
    Oncologist; 2019 Apr; 24(4):e137-e141. PubMed ID: 30446583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
    Lee DH; Tsao MS; Kambartel KO; Isobe H; Huang MS; Barrios CH; Khattak A; de Marinis F; Kothari S; Arunachalam A; Cao X; Burke T; Valladares A; de Castro J
    PLoS One; 2018; 13(8):e0202865. PubMed ID: 30148862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
    de Castro J; Tagliaferri P; de Lima VCC; Ng S; Thomas M; Arunachalam A; Cao X; Kothari S; Burke T; Myeong H; Grattan A; Lee DH
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28748556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
    Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
    Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases.
    Evans M; O'Sullivan B; Smith M; Hughes F; Mullis T; Trim N; Taniere P
    Pathol Oncol Res; 2019 Oct; 25(4):1401-1409. PubMed ID: 30094734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and types of
    Lemine Sow M; El Yacoubi H; Moukafih B; Balde S; Akimana G; Najem S; El Khoyaali S; Abahssain H; Chaibi A; Zeb Khan S; Trapani D; Benzekri A; Ghaouti M; Gamra L; Mestari A; Kettani F; Rahali Y; Mrabti H; Elghissassi I; Errihani H
    Tumori; 2021 Aug; 107(4):335-340. PubMed ID: 33079008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of EGFR Mutations and Clinico-Pathological Characteristics of Chilean Lung Cancer Patients.
    Gejman R; González S; Muñoz-Medel M; Nervi B; Sánchez C; Ibáñez C; Peña J; Madrid J; Briones J; Pérez P; Garrido M; Galindo H
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):1-4. PubMed ID: 30677862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    Aye PS; Tin Tin S; McKeage MJ; Khwaounjoo P; Cavadino A; Elwood JM
    BMC Cancer; 2020 Jul; 20(1):658. PubMed ID: 32664868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.
    Enewold L; Thomas A
    PLoS One; 2016; 11(6):e0156728. PubMed ID: 27294665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.
    Hung A; Lee KM; Alba PR; Li Y; Gao AZ; Hintze BJ; Efimova OV; Shenolikar R; Pavilack M; Simmons D; Kelley MJ; Lynch JA; Reed SD
    Cancer Treat Res Commun; 2021; 27():100327. PubMed ID: 33549984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
    Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
    J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
    Tsao MS; Sakurada A; Ding K; Aviel-Ronen S; Ludkovski O; Liu N; Le Maître A; Gandara D; Johnson DH; Rigas JR; Seymour L; Shepherd FA
    J Thorac Oncol; 2011 Jan; 6(1):139-47. PubMed ID: 21107284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.
    Berg J; Fjellbirkeland L; Suhrke P; Jebsen P; Lund-Iversen M; Kleinberg L; Helgeland L; Brustugun OT; Helland Å
    Acta Oncol; 2016; 55(2):149-55. PubMed ID: 26313507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
    Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.